Surefire Medical Launches Precision Direct-to-Tumor Infusion System at CIRSE

September 25, 2015—Surefire Medical, Inc. announced the launch of its Precision targeted delivery infusion system for direct-to-tumor embolization procedures in minimally invasive primary and secondary liver cancer treatments. The company is introducing the device at CIRSE 2015, the Cardiovascular and Interventional Radiological Society of Europe’s annual scientific meeting being held September 26–30 in Lisbon, Portugal.

On September 1, the company announced that the new Surefire Precision infusion system received US Food and Drug Administration clearance. On May 8, Surefire Medical announced European CE Mark approval for the device.

According to the company, key features of the Surefire Precision system include an expandable tip to achieve effective pressure control; ultrathin catheter construction and lubricious hydrophilic coating that allows the device for enhanced tracking, providing access to a wide-range of vessel sizes and complex anatomies; and compatibility with up to 500-µm beads to enable treatment of various disease types. A recent prospective clinical trial showed that the Surefire infusion technology increased drug delivery into tumors by as much as 90% and reduced nontarget delivery to healthy tissue, noted Surefire Medical.

In the company’s press release, Prof. Geert Maleux, MD, of the Department of Radiology, University Hospitals Leuven in Belgium, commented, “Chemo- and radioembolization techniques are becoming valuable treatment options in selected patients with unresectable liver tumors. The Precision catheter provides us with a new interventional tool to safely and effectively deliver drug-eluting and yttrium-90 microspheres within the tumor."